MedPath

MK0524 Asthma POC Study (0524-008)(COMPLETED)

Phase 2
Completed
Conditions
Asthma
Registration Number
NCT00783601
Lead Sponsor
Merck Sharp & Dohme LLC
Brief Summary

The purpose of the study is to demonstrate the benefit of MK0524 compared to placebo in patients with chronic asthma.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
130
Inclusion Criteria
  • Has symptoms of chronic asthma (shortness of breath, wheezing, chest tightness, etc.) for at least 1 year
  • Nonsmoker for at least 1 year with a smoking history of no more than 7 pack-years (i.e., 1 pack per day for 7 years)
Read More
Exclusion Criteria
  • Any clinically significant disease of heart, intestinal, kidney, liver, lung or uncontrolled blood pressure
  • Any surgery within 4 weeks prior to Visit 1
  • Patient is intending to move or vacation for more than 5 days during the study
  • Patient is pregnant or breast-feeding
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
To demonstrate benefits of MK0524 compared with placebo on Forced Expiratory Volume in 1 second (FEV1)Last 2 weeks of each treatment period
Secondary Outcome Measures
NameTimeMethod
To determine the benefits of MK0524 as compared with placebo on the key secondary endpoints (Daytime & Nighttime Asthma Symptoms scoresLast 2 weeks of each treatment period
© Copyright 2025. All Rights Reserved by MedPath